• A Janus kinase 3 inhibitor is attractive as a possible treatment of various autoimmune diseases since its function is mainly restricted to lymphocytes. (wikipedia.org)
  • As a consequence they play pivotal roles in the patho-physiology of many diseases including neoplastic and autoimmune diseases. (openrheumatologyjournal.com)
  • Janus kinase inhibitors can be classed in several overlapping classes: they are immunomodulators, they are DMARDs (disease-modifying antirheumatic drugs), and they are a subclass of tyrosine kinase inhibitors. (wikipedia.org)
  • Gandotinib (LY-2784544) against JAK2 for myeloproliferative neoplasms. (wikipedia.org)
  • Pacritinib (SB1518) for relapsed lymphoma and advanced myeloid malignancies, also myelofibrosis, myeloproliferative neoplasms and myelodysplastic syndrome. (wikipedia.org)
  • 3. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. (nih.gov)
  • 4. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. (nih.gov)
  • 6. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells. (nih.gov)
  • 8. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. (nih.gov)
  • 9. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms. (nih.gov)
  • 10. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. (nih.gov)
  • 11. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. (nih.gov)
  • 14. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target? (nih.gov)
  • 16. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. (nih.gov)
  • With the intent of dissecting the molecular complexity of Philadelphia-negative myeloproliferative neoplasms (MPN), we designed a target enrichment panel to explore, using next-generation sequencing (NGS), the mutational status of an extensive list of 2000 cancer-associated genes and microRNAs. (nih.gov)
  • A Janus kinase 3 inhibitor is attractive as a possible treatment of various autoimmune diseases since its function is mainly restricted to lymphocytes. (wikipedia.org)
  • CHZ868 - a type II JAK2 inhibitor for use in myeloproliferative disorders and chronic myelomonocytic leukemia (CMML). (wikipedia.org)
  • 12. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. (nih.gov)
  • 5. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. (nih.gov)
  • It is used in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis and various skin conditions. (wikipedia.org)
  • Deucravacitinib is currently in clinical trials for psoriatic arthritis, inflammatory bowel disease and systemic lupus erythematosus. (wikipedia.org)
  • Janus kinase inhibitors can be classed in several overlapping classes: they are immunomodulators, they are DMARDs (disease-modifying antirheumatic drugs), and they are a subclass of tyrosine kinase inhibitors. (wikipedia.org)